Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of efficacy and safety of insulin detemir in combination with insulin aspart and biphasic insulin aspart 30 [insulin aspart/insulin protamine aspart] in type 2 diabetes mellitus.

Trial Profile

Comparison of efficacy and safety of insulin detemir in combination with insulin aspart and biphasic insulin aspart 30 [insulin aspart/insulin protamine aspart] in type 2 diabetes mellitus.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin detemir (Primary) ; Insulin aspart/insulin protamine aspart
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms PreFER
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 01 Jul 2009 Actual end date (1 Mar 2005) added as reported by ClinicalTrials.gov.
    • 01 Jan 2009 Results have been published in Diabetes, Obesity and Metabolism.
    • 01 Jan 2009 Primary endpoint 'Proportion of glycosylated haemoglobin' has been met according to results published in Diabetes, Obesity and Metabolism.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top